March 26, 2023

Forget about the Hippocratic Oath and just throw it out of the window in Bio Inc. Nemesis.

unnamed (1).jpg

Forget about the Hippocratic Oath and just throw it out of the window in Bio Inc. Nemesis.

Independent developers DryGin Studios will be looking to bring their next level of malpractice to Android and iOS with Bio Inc. Nemesis. If you are not aware of Bio Inc., it can be best described as a biomedical strategy simulator in which you determine the ultimate fate of a victim by developing the most lethal illness possible. It’s worth noting that is a wonder why the game saw a 400,000 download up tick this month with the increased news surrounding the coronavirus.

In Bio Inc. Nemesis, you will be able to recruit from a pool of 30-plus doctors, some of which includes a buttoned-up physicians, a wacky-tobacky smoking alternative medicine practitioners, and more. Some such as Dr. Condo will have vaguely familiar names and faces. Bio Inc. Nemesis will have you prescribing large doses of the coronavirus, afflicting patients with diseases and infections before opposing physicians can practice life-saving medicine. Build up energy to unleash a myriad of maladies on patients, shutting down their nervous, circulatory, and respiratory systems while A.I.-controlled medics employ preventative measures.

Bio Inc. Nemesis was born from us thinking about how we could take Bio Inc. to the next level, and deliver on what fans of the first game really wanted. Infecting patients with horrific diseases is ironically going to make you feel good.” – J-F

Bio Inc. Nemesis will feature three campaigns each of which will help you to learn how to become the best-worst doctors in the business. In Events and Challenges, new medical mysteries will be thrown your way and you can even go head-to-head in Arena mode with a competitive ladder system and rewards.

Bio Inc. Nemesis will be available as a free download on the App Store and Google Play on Feb. 26. For more information on Bio Inc. Nemesis, visit the official website.